<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330314</url>
  </required_header>
  <id_info>
    <org_study_id>HM-INS-103</org_study_id>
    <nct_id>NCT03330314</nct_id>
  </id_info>
  <brief_title>Molar Potency Study of HM12460A in Healthy Subjects</brief_title>
  <official_title>An Open Label, Fixed-Sequence, Glucose Clamp Study to Compare Molar Potency of HM12460A and Insulin Glargine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Actual">February 8, 2018</completion_date>
  <primary_completion_date type="Actual">February 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose assessment of HM12460A and insulin glargine over the entire dosing period</measure>
    <time_frame>1 month</time_frame>
    <description>- Comparison of HM12460A to insulin glargine based on blood glucose profile generated by intravenous infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of HM12460A</measure>
    <time_frame>1 month</time_frame>
    <description>- Maximum concentration of HM12460A over the entire dosing period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of HM12460A</measure>
    <time_frame>1 month</time_frame>
    <description>- Area Under the Curve of HM12460A over the entire dosing period</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion (Dose A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion (Dose B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion (Dose C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HM12460A</intervention_name>
    <description>HM12460A is a long-acting insulin</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2: Cohort A</arm_group_label>
    <arm_group_label>Part 2: Cohort B</arm_group_label>
    <arm_group_label>Part 2: Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females must be non-pregnant and non-lactating

          -  Males must be surgically sterile or using an acceptable contraceptive method

        Exclusion Criteria:

          -  History of any major surgery within 6 months prior to screening

          -  Use of any new prescription or non-prescription drug in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanmi Investigative Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

